Jeffrey D. Nornhold
Director/Board Member at Impax Laboratories (Taiwan), Inc.
Profile
Jeffrey D.
Nornhold is currently a Director at Impax Laboratories (Taiwan), Inc. He previously worked as a Vice President-Quality Operations at Actavis, Inc. and as a Senior Vice President-Technical Operations at Impax Laboratories LLC from 2011 to 2018.
Prior to that, he was a Vice President-International Quality Operations at Allergan Ltd.
(Ireland) from 2004 to 2011.
He is also currently a Senior VP-Pharmaceutical Operations & Development at Myovant Sciences Ltd.
from 2018 to 2023.
Nornhold received his undergraduate degree from Bowling Green State University in 1988 and his MBA from USC Marshall School of Business in 2008.
Jeffrey D. Nornhold active positions
Companies | Position | Start |
---|---|---|
Impax Laboratories (Taiwan), Inc.
Impax Laboratories (Taiwan), Inc. Pharmaceuticals: MajorHealth Technology Impax Laboratories (Taiwan), Inc. engages in the research, development and manufacturing of oral controlled-release dosage forms of generic drugs. It also involves in the formulation and clinical development of alternate dosage forms of drugs for diseases in the central nervous system. Its products include branded pharmaceutical product such as IPX066 and generic pharmaceutical products such as Acarbose, Dantrolene Sodium, and Fenofibrate tablets. The company was founded on May 4, 2007 and is headquartered in Miaoli, Taiwan. | Director/Board Member | - |
Former positions of Jeffrey D. Nornhold
Companies | Position | End |
---|---|---|
MYOVANT SCIENCES LTD. | Chief Operating Officer | 2023-05-31 |
Impax Laboratories LLC
Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | 2018-06-30 |
ALLERGAN PLC | Corporate Officer/Principal | 2011-04-30 |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | - |
Training of Jeffrey D. Nornhold
Bowling Green State University | Undergraduate Degree |
USC Marshall School of Business | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Health Technology |
Impax Laboratories LLC
Impax Laboratories LLC Pharmaceuticals: MajorHealth Technology Impax Laboratories LLC operates as a technology based specialty pharmaceutical company. It engages in the development, manufacture, and marketing of controlled-release and niche generics. The company was founded on December 14, 1999 and is headquartered in Bridgewater, NJ. | Health Technology |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Impax Laboratories (Taiwan), Inc.
Impax Laboratories (Taiwan), Inc. Pharmaceuticals: MajorHealth Technology Impax Laboratories (Taiwan), Inc. engages in the research, development and manufacturing of oral controlled-release dosage forms of generic drugs. It also involves in the formulation and clinical development of alternate dosage forms of drugs for diseases in the central nervous system. Its products include branded pharmaceutical product such as IPX066 and generic pharmaceutical products such as Acarbose, Dantrolene Sodium, and Fenofibrate tablets. The company was founded on May 4, 2007 and is headquartered in Miaoli, Taiwan. | Health Technology |
- Stock Market
- Insiders
- Jeffrey D. Nornhold